2. Search Result
Search Result
Results for "

sucrase

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Biochemical Assay Reagents

8

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W015611
    L-(+)-Arabinose

    		Endogenous Metabolite Metabolic Disease
    L-(+)-Arabinose selectively inhibits intestinal sucrase activity in a noncompetitive manner and suppresses the plasma glucose increase due to sucrose ingestion.
    L-(+)-Arabinose
  • HY-42680
    D-Tagatose

    D-(-)-Tagatose

    		 Endogenous Metabolite Metabolic Disease Inflammation/Immunology Cancer
    D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes .
    D-Tagatose
  • HY-E70130
    Snailase, Snail gastrointestinal

    		Others Others
    Snailase, Snail gastrointestinal is an enzyme mixture composed of more than 20 enzymes, which is often used for enzymatic hydrolysis of purified flavonoid glycosides. Snailase can be obtained from the digestive tract and includes cellulase, sucrase, hemicellulase, pectinase, polygalacturonase, protease, etc .
    Snailase, Snail gastrointestinal
  • HY-119741
    Salacinol

    		Glycosidase Lipase Metabolic Disease
    Salacinol, compound found in Salacia reticulata, is an orally active α-glucosidase/lipase inhibitor. Salacinol inhibits enzymatic activity of intestinal maltase (IC50 = 3.2 μg/mL, Ki = 0.31 μg/mL), sucrase (IC50 = 0.84 μg/mL, Ki = 0.32 μg/mL), and isomaltase (IC50 = 0.59 μg/mL, Ki = 0.47 μg/mL), and inhibits increases in serum glucose levels in sucrose-loaded rats. Salacinol also inhibits pancreatic lipase and lipoprotein lipase. Salacinol can be used for the research of diabetes mellitus .
    Salacinol
  • HY-W015611R
    L-(+)-Arabinose (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    L-(+)-Arabinose (Standard) is the analytical standard of L-(+)-Arabinose. This product is intended for research and analytical applications. L-(+)-Arabinose selectively inhibits intestinal sucrase activity in a noncompetitive manner and suppresses the plasma glucose increase due to sucrose ingestion.
    L-(+)-Arabinose (Standard)
  • HY-Y0319D
    Acetic acid lead

    		Endogenous Metabolite AMPK Reactive Oxygen Species (ROS) Caspase Fungal PPAR Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Acetic acid lead is a carboxylic acid and short-chain fatty acid (SCFAs). Magnesium acetate tetrahydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Acetic acid lead exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Acetic acid lead regulates energy metabolism. Acetic acid lead has anticancer activity against gastric cancer. Acetic acid lead induces writhing reaction and ulcerative colitis. Acetic acid lead can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain .
    Acetic acid lead
  • HY-131114
    Valiolamine

    		Glycosidase Infection
    Valiolamine, an aminocyclitol, is an alpha-glucosidase inhibitor. Valiolamine has potent alpha-glucosidase inhibitory activity against porcine intestinal sucrase, maltase and isomaltase. Valiolamine binds to porcine intestinal maltase and sucrase with Ki values of 350 nM and 30 nM, respectively .
    Valiolamine
  • HY-P2723
    Dextran sucrase

    		Endogenous Metabolite Metabolic Disease
    Dextran sucrase is an extracellular glucosyltransferase (GTF) that catalyses the transfer of D-glucopyranosyl residues from sucrose to dextran .
    Dextran sucrase
  • HY-N1102
    Vasicinol

    6-Hydroxypeganine

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Vasicinol is a reversible inhibitor of sucrase (IC50: 250 μM). Vasicinol is a HbF inducer. Vasicinol also inhibits Angiotensin-converting Enzyme (ACE). Vasicinol is apyrroquinazoline alkaloid that can be isolated from Adhatoda vasica .
    Vasicinol
  • HY-N3974
    Griffipavixanthone

    (+)-Griffipavixanthone

    		 Apoptosis Cancer
    Griffipavixanthone can be extracted from Garcinia schomburgkiana. Griffipavixanthone induces cell apoptosis through mitochondrial apoptotic pathway accompanying with ROS production. Griffipavixanthone is an anti-cancer agent. Griffipavixanthone is a weak sucrase inhibitor (IC50: 4.58 mM) .
    Griffipavixanthone
  • HY-42680R
    D-Tagatose (Standard)

    D-(-)-Tagatose (Standard)

    		 Reference Standards Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    D-Tagatose (Standard) is the analytical standard of D-Tagatose (HY-42680). This product is intended for research and analytical applications. D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
    D-Tagatose (Standard)
  • HY-42680S1
    D-Tagatose-13C-1

    D-(-)-Tagatose-13C-1

    		 Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    D-Tagatose- 13C-1 is the 13C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
    D-Tagatose-13C-1
  • HY-42680S
    D-Tagatose-13C

    D-(-)-Tagatose-13C

    		 Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    D-Tagatose- 13C is the 13C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
    D-Tagatose-13C
  • HY-182289
    LY-23

    		Glycosidase Metabolic Disease
    LY-23 is an orally active α-glucosidase inhibitor (Ki = 0.05 μM), with IC50 values of 0.18 μM, 0.14 μM and 0.51 μM against maltase, sucrase and isomaltase, respectively. LY-23 reduces the level of postprandial blood glucose elevation. LY-23 is applicable to research related to postprandial hyperglycemia .
    LY-23
  • HY-131114R
    Valiolamine (Standard)

    		Glycosidase Reference Standards Infection
    Valiolamine (Standard) is the analytical standard of Valiolamine (HY-13114). This product is intended for research and analytical applications. Valiolamine, an aminocyclitol, is an alpha-glucosidase inhibitor. Valiolamine has potent alpha-glucosidase inhibitory activity against porcine intestinal sucrase, maltase and isomaltase. Valiolamine binds to porcine intestinal maltase and sucrase with Ki values of 350 nM and 30 nM, respectively .
    Valiolamine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: